TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04838665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate and 2.5% phenylephrine
Description: Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% cyclopentolate and 2.5% phenylephrine
Description: Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate and 2.5% phenylephrine
Description: Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% tropicamide + 0.5% phenylephrine
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine with a cotton wick
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% tropicamide + 0.5% phenylephrine with a cotton wick
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide + 0.5% phenylephrine with a cotton wick
Description: Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
Study: NCT03476564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit E
Description: will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
Study: NCT01995578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose 5'-azacitidine
Description: 5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
Study: NCT02803528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is going to be used as the direct pulp capping material

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is going to be used as the direct pulp capping material in the second group
Study: NCT02633410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral tunnel creation
Description: Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral tunnel creation
Description: Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
Study: NCT02452281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: 3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
Study: NCT01378104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa 2a (pegasys)
Description: dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a (pegasys)
Description: These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
Study: NCT02912416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00002860

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Complete surgical resection of metastatic melanoma
Study: NCT01859468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amorphous calcium carbonate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00096668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOCOSOL(R) Paclitaxel
Study: NCT03644654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care group
Description: Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive monitoring group
Description: Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
Study: NCT04215614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Bupivacaine solution
Description: 1:1 ratio 2% lidocaine, and 0.5% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Bupivacaine solution
Description: 1:1 ratio 2% lidocaine, and 0.5% bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular block
Description: Ultrasound-guided costoclavicular brachial plexus block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sagittal block
Description: Ultrasound-guided lateral sagittal brachial plexus block
Study: NCT05584254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yeast-beta glucan
Study: NCT04714736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography using DyeVert system
Description: Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary angiography using conventional manual injection syringe.
Description: Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
Study: NCT01195753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HHLivC
Description: multiple infusion of liver cells
Study: NCT03128476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essence of Chicken
Description: Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Essence of Chicken
Description: Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Energy matched)
Study: NCT02154542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurovent Monitor XIII

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurovent Monitor XIII
Study: NCT02748850

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: a blood sample 20 milliliter

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Stem cell donation
Description: The volume of stem cells remained in the tube is recovered
Study: NCT02896829

Intervention type: BEHAVIORAL
Intervention: Interruption of the treatment by Imatinib
Study: NCT01776736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture Correction Girdle
Description: Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
Study: NCT01765842

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Only one cycle of rituximab will be administered in this arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Only one cycle of rituximab will be administered in this arm.
Study: NCT03364361

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture
Description: Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
Study: NCT04062526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: \[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
Study: NCT04728022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program
Description: Mentored high school summer research program
Study: NCT03858036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricrolin+
Description: 1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricrolin+
Description: 1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VEGA UV-A system
Description: The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VEGA UV-A system
Description: The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
Study: NCT02163083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG
Description: Improvement of detection of positive lymphnodes
Study: NCT01020591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic evaluation
Description: evaluation of movement and tissue mobility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic evaluation with treatment
Description: osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
Study: NCT04719494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic balance walking training
Description: Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
Study: NCT02611804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02713165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Participants will consume 84g of raisins per day for 14 days.
Study: NCT01091584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distress thermometer
Description: to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
Study: NCT00514774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol
Description: ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol
Description: ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 600mg twice daily for study days 0 through 28
Study: NCT00759733

Intervention type: PROCEDURE
Intervention: echocardiography
Description: A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.

Intervention type: PROCEDURE
Intervention: echocardiography
Description: A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.

Intervention type: PROCEDURE
Intervention: blood draw for serum B-type natriuretic peptide
Description: A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only

Intervention type: PROCEDURE
Intervention: blood draw for serum B-type natriuretic peptide
Description: A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
Study: NCT00832520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remeron (mirtazapine)
Description: Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None
Study: NCT01582295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Starting dose 40 mg daily
Study: NCT00580372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAD
Description: 3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose cyclophosphamide
Description: Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemopoietic stem cell procurement
Description: Collection target = 10 x 10\^6 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDAP
Description: Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hemopoietic Stem Cell Transplant 1
Description: 4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hemopoietic Stem Cell Transplant 2
Description: 4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: 3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
Study: NCT02859376

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sucrose 24%
Description: Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose 24%
Description: Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
Study: NCT04416347

Intervention type: OTHER
Intervention: SARS-CoV2 Infection
Description: Laboratory confirmed SARS-CoV2

Intervention type: OTHER
Intervention: SARS-CoV2 Infection
Description: Laboratory confirmed SARS-CoV2
Study: NCT03472924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
Study: NCT03726606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens
Description: Bilateral implantation of the same intraocular lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Bilateral implantation of the same intraocular lens.
Study: NCT01112020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHG Catheter Dressing Patch
Description: 2% CHG dressing applied to 7 sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biopatch
Description: Biopatch applied to 7 sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm CHG
Description: Tegaderm CHG IV Securement Dressing applied to 7 sites
Study: NCT03389295

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Target Delineation and Radiation Doses
Description: The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
Study: NCT03911973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib, 150-180MG IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: .75-1.00mg
Study: NCT01761045

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup 1
Description: Consommé soup with Monosodium L-Glutamate (MSG)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup 2
Description: Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soup 3
Description: Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)